Rigel Pharmaceuticals (RIGL) Short-term Investments (2010 - 2026)

Rigel Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $122.3 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 289.76% year-over-year to $122.3 million; the TTM figure through Mar 2026 stood at $122.3 million (up 289.76% YoY), while the FY2025 annual figure was $114.4 million, up 455.89% from the prior year.
• Short-term Investments was $122.3 million for Q1 2026 at Rigel Pharmaceuticals, up from $114.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $122.3 million in Q1 2026 to a low of $9.4 million in Q3 2024.
• Historically, Short-term Investments has averaged $46.1 million across 5 years, with a median of $31.4 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Short-term Investments plunged 77.82% in 2023, then jumped 840.45% in 2025.
• A 5-year view of Short-term Investments shows it stood at $33.7 million in 2022, then fell by 28.45% to $24.1 million in 2023, then slipped by 14.79% to $20.6 million in 2024, then surged by 455.89% to $114.4 million in 2025, then climbed by 6.91% to $122.3 million in 2026.
• The last three Short-term Investments figures came in at $122.3 million (Q1 2026), $114.4 million (Q4 2025), and $88.6 million (Q3 2025), per Business Quant data.